What You Need to Know
• The Food and Drug Administration approved Merck’s new cholesterol pill, Lipfendra, on Thursday.
• Lipfendra, a daily PCSK9 inhibitor, is designed for individuals with high levels of LDL cholesterol.
• The drug can lower LDL cholesterol by up to 60% and costs $10.50 per day, or $315 monthly.
The Food and Drug Administration approved Merck & Co., Inc.’s new cholesterol-lowering medication, Lipfendra, on Thursday. This daily pill is classified as a PCSK9 inhibitor, a category of drugs that previously required injections. Lipfendra is specifically approved for individuals with hypercholesterolemia, characterized by elevated levels of low-density lipoprotein (LDL) cholesterol, often referred to as “bad cholesterol.” Approximately one in four adults in the United States has high LDL cholesterol, which can lead to serious cardiovascular issues. In clinical trials, Lipfendra demonstrated the ability to reduce LDL cholesterol levels by up to 60% after 24 weeks. The drug is priced at $10.50 per day, totaling $315 for a 30-day supply, although Merck anticipates lower out-of-pocket costs for patients.
Why It Matters
The approval of Lipfendra by the Food and Drug Administration is significant as it expands treatment options for individuals with high LDL cholesterol, a condition affecting a substantial portion of the U.S. adult population. The American Heart Association has emphasized the need for more aggressive cholesterol management, recommending specific LDL targets based on individual risk factors. Lipfendra’s mechanism of action differs from that of statins, targeting the PCSK9 protein involved in cholesterol production. This new oral medication may improve adherence to treatment regimens, as it eliminates the need for injections, potentially leading to better health outcomes for patients at risk of heart disease and stroke.
Read the Full Story →
